Quinoline compounds as inhibitors of KRAS
US12378243B2 · kind B2 · utility
0Cited by
44References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 9, 2024 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Feb 9, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.